Annie Wong 黃毅敏
@anmwongNZ
Followers
1K
Following
19K
Media
375
Statuses
4K
🇳🇿Medical Oncologist👩🏻⚕️Senior lecturer University Otago Wellington/Auckland 👩🏻🏫 Mother🤱🏻 Food enthusiast👩🏻🍳#MedEd #melsm #lcsm #globaloncology
Wellington City, New Zealand
Joined December 2013
Inspired by Chinese Ao/NZ writers @plainricedinner @juliezhuu I wrote a personal essay, Yuan Fen 緣份, about being an immigrant oncologist and my Chinese patients. As immigrants, we see each other’s hopes & struggles, so I’m always thrilled i can contribute in my small way
17
11
101
RT @LungSummit: What’s next in the evolving landscape of EGFR and ALK targeting in NSCLC? 🫁. @TommyJohn00 from Australia will explore where….
0
6
0
Great reconnecting with old friends:. Congrats to Tony Huang, post-doc from @paulbeavis4 lab @PeterMacCC @PeterMacRes winning best poster 🤩. Check it out!
0
0
5
🙏 @myESMO .Great talks in our session on trial reporting in precision era:. 🤩careful biomarker planning from get-go. 🤩P1/2 PROMS!. 🤩data visualisation crucial for engagement 🕷️🌋 . 🤩collab collab collab. Team @herbloong x El Helali x Lim 🤩
1
2
24
Always so inspiring @AACRPres Prof Lilian Siu’s Keynote insights @myESMO #ESMOTATAsia25 . 🌏Play to our strengths & 👀 opportunities to collab/complementary trials. 🌏Strategies to improve equity/access to trials. 🌏visions for P1 trials to be patient focus, not just 💊focused
2
10
31
Ok @myESMO #ESMOTATAsia25 #Hongkong has set the standard of care for conference lunch! 🇭🇰🥟. Thanks so much to the organisers! . 🤩🤩🤩
2
0
21
RT @omalirp: Early start to Day 2 #ESMOTATAsia25 with some stats! Dr @anmwongNZ on how to report subgroup analyses in RCTs; IPASS as a good….
0
3
0
Great first day @myESMO #ESMOTATAsia25 . 🤩great cellular therapies panel:.🗣️ on-target off-tumour tox.🗣️when to best use it/best combo . 🤩@apoddc survey highlighting barriers for trials & need for 🌏collabs @pankajpanda86 .@herbloong @danieltanmd @DrBenTran
0
6
29
RT @KoheiShitara: It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collabo….
0
60
0
RT @ADesaiMD: 🎉Out now! "Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?" in @JCOOP_ASCO💉 .#SC….
0
19
0
RT @herbloong: Putting final touches together to my talk😀. Looking forward to welcoming you all to #hongkong 🇭🇰 for #ESMOTATAsia25! Don't b….
0
4
0
RT @NzsOncology: Great opportunity from @CRT_NZ - a grant writing and information session - with a follow up session being held at #NZSO20….
0
1
0
RT @JiaJennyLiu: One week until the inaugural #ESMOTATAsia25 🤩.I'm looking forward to joining global drug development experts in🍜🇭🇰. shari….
0
3
0
RT @KVanLoonMD: I ❤️ the intersection of medicine and the humanities. These are the articles that remind us why we do what we do. Checko….
ascopubs.org
0
13
0
RT @MarioBalsaMD: 💥 New @Nature study on lung cancer in never smokers (LCINS) reveals key mutational forces:. ⚠️ Air pollution (not secondh….
nature.com
Nature - An analysis of data from the Sherlock-Lung study provides insight into the mutational processes that contribute to lung cancer in never smokers, and looks at the possible role of factors...
0
18
0
RT @Florez_Lab: 🎯 EQUAL SPOTLIGHT. After losing multiple family members to lung cancer and being diagnosed at 39, @jillfeldman4 searched fo….
0
14
0
RT @StephenVLiu: The latest episode of the @IASLC podcast previews the upcoming #WCLC25 meeting with the four co-chairs: Drs. @DrJNaidoo @U….
iaslc.org
Join Dr. Narjust Florez and Dr. Stephen Liu on Lung Cancer Considered as they sit down with all four co-chairs of the upcoming IASLC 2025 World Conference on Lu ...
0
10
0
RT @TOGAANZ: 🚨 TOGA’s 2025 Annual Scientific Meeting is fast approaching! . Join leading experts, researchers, and clinicians working to tr….
0
1
0
RT @DrAngelaLamarca: Discussion by @AndresC27622123 who .highlights the importance of #QoL and how @myesmo #MCBS has been modified for thes….
0
5
0
RT @paulbeavis4: Pleased to present the latest work from the lab published in @NatureComms in work led by @kevin_sek:. .
nature.com
Nature Communications - The efficacy of CAR-T cells against solid tumors is still limited by immunosuppressive factors. Here, the authors show that engineering of CAR T cells with A1R enhances...
0
5
0